Like many other nuclear medicine vendors, SMV of Twinsburg, OH,is developing high-energy imaging technologies to image fluorodeoxyglucose,the radiotracer used in most PET studies. At its RSNA booth, SMVwill display both collimated and coincidence
Like many other nuclear medicine vendors, SMV of Twinsburg, OH,is developing high-energy imaging technologies to image fluorodeoxyglucose,the radiotracer used in most PET studies. At its RSNA booth, SMVwill display both collimated and coincidence detection-based high-energymethods, according to Robert Ripley, director of corporate communications.
SMV will also debut a new motion-correction program designedto work with its Transmission Attenuation Correction (TAC) productand its Restore resolution recovery algorithm.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.